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Abstract 24 
Exposure assessment is a key step in determining risks to chemicals in consumer goods including 25 
personal care products (PCPs). Exposure models can be used to estimate exposures to chemicals 26 
in the absence of biomonitoring data and as tools in chemical risk prioritization and screening.   27 
We apply a PCP exposure model based on the product intake fraction (PiF), which is defined as 28 
the fraction of chemical in a product that is taken in by the exposed population, to estimate 29 
chemical intake based on physicochemical properties and PCP usage characteristics. The PiF can 30 
be used to estimate route and pathway specific exposures during both the use- and disposal-31 
stages of a product. As a case study, we stochastically quantified population level exposures to 32 
parabens in PCPs, and compared estimates to biomarker values. We estimated exposure based on 33 
the usage of PCPs in the female US population, taking into account population variability, 34 
product usage characteristics, paraben occurrence in PCPs, and the PiF. Intakes were converted 35 
to urine levels and compared to NHANES (National Health and Nutrition Examination Survey) 36 
biomonitoring data. Results suggest that for parabens, chemical exposure during product use is 37 
substantially larger than environmentally mediated exposure after product disposal. Modeled 38 
urine concentrations reflect well the NHANES variation of three orders of magnitude across 39 
parabens for the 50
th
, 75
th
, 90
th
, and 95
th
 percentiles and were generally in good agreement with 40 
measurements, when taking uncertainty into account. This study presents an approach to estimate 41 
multi-pathway exposure to chemicals in PCPs and can be used as a tool within exposure based 42 
screening of chemicals as well in higher tier exposure estimates. 43 
 44 
Keywords: exposure modeling, dermal exposure, inhalation exposure, multi-media studies, 45 
personal exposure, population based studies 46 
47 
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 48 
1. Introduction 49 
In order to inform risk assessment of chemicals in cosmetics and personal care products 50 
(PCPs) an understanding of individual and population level exposure is required.
1,2
 The need for  51 
exposure estimates based on various chemical uses is highlighted by the recent advances in high-52 
throughput exposure models for chemical prioritization
3,4
 which can also be combined with high-53 
throughput toxicity estimates to inform risk.
5,6
 Historically, these modeling efforts have focused 54 
on far-field environmentally mediated exposures and less on near-field pathway exposures 55 
occurring indoors and during product use.
3,7
 Usage of PCPs has been shown to be well correlated 56 
with exposure
8,9
 and use-phase exposure has been estimated to be greater than environmentally 57 
mediated exposure.
10,11
 Modeling techniques can be used to estimate near-field and use-phase 58 
exposures to chemicals in PCPs and can be used to further enhance chemical prioritization 59 
methods for chemicals in consumer products.
6
 60 
Several calculations have been developed to estimate chemical intake via PCP use and are 61 
based on multiplicative models
1,2,12
 using a set skin permeation fraction often derived from the 62 
literature and do not necessarily take exposure duration (e.g. rinse-off versus leave-on into 63 
account).
1
 On the other hand, models have been developed to estimate the skin permeation 64 
coefficient of a chemical
13,14
 and chemical uptake into the skin.
15,16
 Skin permeation models 65 
provide the advantage that they can be applied to chemicals based on physicochemical properties 66 
(i.e. octanol-water partition coefficient, Kow, and molecular weight) thereby lending themselves 67 
to computationally based calculations rather than relying on data from the literature which is not 68 
conducive to multiple chemical calculations. Furthermore, models used to estimate exposure to 69 
chemicals applied dermally vary in mathematical complexity, for example by assuming only one 70 
chemical fate pathway (i.e. dermal uptake),
15
 or only providing complex numerical solutions.
16
 71 
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Modeling frameworks are currently being developed to combine dermal uptake with the concept 72 
of the product intake fraction, PiF, defined as the fraction of the chemical in a product that is 73 
eventually taken in by the exposed individual(s)/population.
17
 These models can be applied to 74 
predict chemical intake via several different pathways such as dermal uptake, inhalation intake 75 
and gaseous dermal uptake of volatilized chemicals, and to environmentally mediated exposure 76 
after product disposal. The advantage of this multi-pathway approach is that the relative 77 
contribution of each pathway can be estimated and does not assume that exposure only occurs 78 
via dermal uptake of product applied to the skin and allows for comparison between use-phase 79 
and disposal-phase exposures. 80 
 Such models, however, have yet to be evaluated on a population level using for example, 81 
biomarker data. Additionally, exposure is often estimated based on the usage of a single product 82 
rather than an aggregate analysis taking into account usage of multiple products containing a 83 
given chemical
1,2,15
, which may underestimate a consumer’s entire exposure for chemicals found 84 
in multiple product types. Cowan-Ellsberry and Robison
1
 and Gosens et al.
2
 present aggregate 85 
exposure estimates for parabens in PCPs, however their estimates do not use a skin permeation 86 
model nor are their estimates validated against biomarker data. Delmaar et al.
15
 estimated 87 
aggregate exposure to diethyl phthalate using a skin permeation model, however they only 88 
consider the dermal exposure pathway. The application of a multi-pathway exposure model to 89 
estimate cosmetic intake has not been validated on a population level nor applied across multiple 90 
product types to yield aggregate exposure estimates. To address this gap, the product intake 91 
fraction concept would need to be adapted to several PCPs and validated against population level 92 
data. Evaluation of a PCP exposure model using data rich chemicals will build further 93 
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confidence in these techniques such that they can be incorporated into Tier 1 exposure and risk 94 
screening approaches and used on a broader range of chemicals. 95 
 In this paper, we apply the PiF concept to model chemical intake due to PCP usage using 96 
parabens as a case study. In order to compare the estimated intakes to population-based 97 
biomonitoring data we probabilistically combined the PiF calculations with aggregate exposure 98 
considerations to capture population variability, focusing on a class of widely used chemicals. 99 
This type of analysis is referred to as a Tier 2 probabilistic exposure estimate
18
 and is more 100 
detailed than point estimates often used in screening approaches (Tier 1).
6
 Parabens are 101 
commonly used in PCPs and cosmetics as preservatives, are readily absorbed into the skin,
19
 are 102 
detectable in urine,
20
 and thereby provide a good PCP exposure case study. Urinary biomarker 103 
data is available for the US population from NHANES (National Health and Nutrition 104 
Examination Survey)
21
 where parabens have been detected in ~99% of the population.
22
 105 
Additionally, parabens are suspected endocrine disruptors
23,24
 and these exposure calculations 106 
provide a basis for informing risk when combined with toxicity, bioactivity, or allowable dose 107 
data.
17
 This study therefore aims to: 108 
1. Estimate and contrast modeled product intake fraction for various exposure pathways 109 
(including near and far-field exposures) for parabens in a variety of PCPs and cosmetics 110 
while accounting for both chemical specific properties and product use characteristics. 111 
2. Develop a stochastic method to produce population distributions of exposure resulting 112 
from the usage of multiple PCPs.  113 
3. Evaluate the stochastic method by comparing its predictions with NHANES urine 114 
concentrations at different percentiles (50
th
 to 95
th
) of exposure in the US population. 115 
2. Methods 116 
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We used four common parabens methyl, ethyl, propyl, and butyl paraben (MeP, EtP, PrP, 117 
BuP, respectively) and eleven commonly used personal care products (PCPs) as a case study. We 118 
included rinse-off products (shampoo, conditioner, facial cleanser, body wash) and leave-on 119 
products (body lotion, face cream, night cream, deodorant, foundation, eye shadow, and lipstick). 120 
We studied the U.S. female population due to the availability of urine biomarker data
21
 and the 121 
significantly higher exposure of the female versus male population to parabens.
22
  122 
2.1 Product Intake Fraction  123 
We used the product intake fraction (PiF) metric to assess the fraction of parabens in 124 
products that humans are exposed to a) during product use and b) via subsequent environmental 125 
emissions after product use. The PiF is defined as the ratio of the amount of chemical in a 126 
product that is taken in by humans and the amount of chemical contained in that product and 127 
depends on physicochemical properties as well as product use characteristics.
17
 Once a product is 128 
applied we assumed that it can undergo the following pathways: direct dermal uptake into the 129 
skin, volatilization to air, and washed down-the-drain after the product is rinsed off. Following 130 
from these pathways, we calculated a PiF for each of the following exposure pathways: dermal 131 
uptake of chemical in an aqueous product (PiF
derm,aq
), inhalation of chemical from the volatilized 132 
product (PiF
inh
), gaseous dermal uptake of chemical from the volatilized product (PiF
derm,gas
), 133 
and environmentally mediated chemical intake due to disposal after product use (PiF
disp
), for 134 
each paraben and each PCP type. 135 
The expression for dermal uptake of chemicals in aqueous products into the skin (PiF
derm,aq
) 136 
is based on a two-compartment mass balance between product and skin and yields the following 137 
solution (see Table S1 in Supplementary Information (SI)): 138 
 tkk
kk
k
PiF
 )(
paps
psaqderm, papse1



                           (1) 139 
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where )h( 
1
ps
k  and )h( 
1
pa
k  are the product-skin and product-air transfer rates, respectively and 140 
t (h) is the exposure time, that is the duration that the product stays on the skin before being 141 
washed-off. The transfer rates psk  and pak  are both functions of the thickness of product on the 142 
skin, in addition to chemical specific parameters such as the aqueous skin permeation 143 
coefficient,
aq
pK (cm h
-1
) and the air-water partition coefficient (Kaw) respectively. Expressions for 144 
the intake of volatilized chemical via inhalation (PiF
inh
) and gaseous dermal uptake (PiF
derm,gas
) 145 
are given in SI, Table S1, and are summed with PiF
derm,aq
 to constitute the total use-stage, PiF
use
, 146 
via these exposure routes. 147 
The PiF associated with product disposal, PiF
disp
 (SI, Table S1), was modeled as the fraction 148 
of chemical not taken in during use and subsequently washed down the drain into a waste water 149 
treatment plant (WWTP) and then released to environmental compartments (air, water, soil). The 150 
subsequent environmental intake fractions (iF) were calculated using the USEtox model.
25
 151 
Finally, a chemical and product specific PiF
tot
 can be defined as the sum of chemical intakes via 152 
all considered pathways (i.e., PiF
derm,aq
, PiF
derm,gas
, PiF
inh
, PiF
disp
) and represents the total 153 
chemical intake via all exposure routes. More details on the calculation of the various pathway 154 
and route specific PiFs can be found in the SI (Section S1). 155 
We note that some personal care products may also lead to non-dietary ingestion exposure, 156 
for example mouthwash and toothpaste, however these products are not reported to contain 157 
parabens
12,26
 and were thus not included in the model. An ingestion PiF can be readily 158 
incorporated into this modeling framework and can take the value of the fraction of product that 159 
is ingested per product use. For example, for toothpaste Bremmer et al.
27
 used measured values 160 
to estimate a toothpaste ingestion fraction. We did not include an ingested fraction for lipstick as 161 
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the resulting median PiF
derm,aq
 was already larger than 50% for all parabens, and previously 162 
assumed fixed ingestion fractions for lipstick can vary greatly (e.g. from 0.1-100%).
4,27
 163 
2.2 Total daily intake  164 
The PiF
tot
 can then be used to calculate daily intake for a given chemical in a product and can 165 
be summed across several different products (p) to calculate an aggregate chemical intake, I (mg 166 
kg
-1
 d
-1
) as 167 
BW
fMPiF
I


p
pp
tot
p  
                            (2) 168 
where Mp (mg d
-1
), pf , and BW (kg) are the daily mass of product applied, fraction of chemical 169 
in the product, and body weight, respectively.  170 
2.3 Monte Carlo Analysis, Model Parameterization, and Aggregate Exposure 171 
Several of the parameters used as input to model the intake of chemicals in PCPs are subject 172 
to population variability, i.e. can have a range of possible values depending on individual 173 
characteristics and behavior within the studied population. We used Monte Carlo (MC) analysis 174 
to incorporate this population variability into our intake calculations. The parameters included in 175 
the analysis as well as their distributions are listed in SI, Table S5. The MC analysis was carried 176 
out for each product and chemical combination by generating 10
5
 random values for each input 177 
parameter from the given probability distribution and using these values to calculate an intake 178 
distribution. Thus in total for four parabens in 11 PCPs yields 44 calculated intake distributions. 179 
We note that the MC analysis considered variables to be independent and potential impacts of 180 
variable correlations were not assessed. 181 
Several key parameters dictate the calculated PiF and intake for a given product-chemical 182 
combination and include the aqueous skin permeation coefficient, ,
aq
pK  the daily amount of 183 
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product used, ,pM  and the fraction of chemical in the product, pf  (Eq. 2). We collected 184 
empirical values of 
aq
pK  for parabens conducted in different media such as an aqueous solution 185 
or with an added alcohol and based the input distribution on these values
28–33
 (Table 1 and S3). 186 
For the daily mass of product usage, we used distribution data from Loretz et al.
34–36
 as these 187 
data pertain specifically to the U.S. female population and detailed information on distributions 188 
were available for the MC analysis. Generally, there is limited information available on the 189 
chemical composition of consumer products, including PCPs.
26
 We collected fraction paraben 190 
content information from various sources
1,12,37
 and aggregated this data into a uniform 191 
distribution (see SI Section S3 for details) with example values for shampoo and body lotion in 192 
Table 1. 193 
Up until this point, all calculations were described for a given product-chemical combination 194 
used by the exposed population and do not account for the population with zero exposure. In 195 
reality, different consumers use different combinations of products, with some products 196 
containing paraben(s) and some not. Thus, in order to calculate aggregate exposure to PCPs, the 197 
probability of occurrence of a given chemical within a PCP (percentage of products with a given 198 
paraben) and the probability of product use (percentage of population that uses a given product) 199 
need to be taken into account
1
 (Figure S4, SI). The initial distributions created for the chemical 200 
intake of the exposed population are thus adjusted for the unexposed population by adding the 201 
appropriate amount of zeros representing non-exposure to the 44 distributions of 10
5
 values 202 
calculated for the exposed population. 203 
2.4 Product co-use 204 
To calculate the population exposure to parabens, the co-use of PCPs should also be taken 205 
into account. For a given paraben there are eleven intake distributions representing each product 206 
 10 
 
with several entries representing zero exposure based on the exposure probability; we randomly 207 
permeated these distributions and then summed intake across products. This yields a single 208 
aggregated intake distribution for each paraben (four distributions in total) with each entry 209 
representing a random sum of product intake percentiles with some products having zero intakes. 210 
We note that paraben exposure can occur via other media such as food and dust,
19,38,39
 however 211 
these media have been estimated to contribute substantially less to exposure levels when 212 
compared to those occurring from direct PCP use.
1,12,39
   213 
To demonstrate the potential usage of the PiF for risk screening, we also applied Eq. (2) 214 
using the 99
th
 percentiles for all values (except body weight, which was set to a constant 75 kg) 215 
and added intake across all eleven products to yield a high-end usage scenario. This intake 216 
estimate represents a user who uses all eleven products which all contain parabens, and does not 217 
take into account any of the exposure adjustments described above. This intends to represent the 218 
very high-end of potential exposure, within the intended use of PCPs.  219 
2.5 Converting external intake into urine concentrations 220 
The inclusion of the MC analysis to produce intake distributions also allows for comparison 221 
to NHANES biomonitoring data which is in the form of population percentiles.
21
 In order to 222 
compare modeled intakes to biomonitoring data, we converted the dose taken in into urine 223 
concentrations based on the urinary excretion fraction, ,UEf  of the chemical. Following Angerer 224 
et al.
40
 the creatinine corrected chemical content in urine, ,)mg (mg 
1
excreted intake Cr
C  can be 225 
estimated as  226 
24h
UE
Cr
Cr
fBWI
C

                  (3) 227 
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where )d (mg 
1
excreted24h
Cr  is the daily creatinine excretion rate. There is very limited data on 228 
UEf  for parabens available in the literature.
41
 Thus, we estimated UEf  values based on measured 229 
in vitro renal and hepatic clearance rates.
42,43
 Uncertainty in UEf  was included in the analysis by 230 
setting upper and lower bounds and running two sets of MC calculations using these high and 231 
low bounds of UEf  (see SI, Section S5). We also added UEf  and hCr24 from Eq. (3) to the Monte 232 
Carlo analysis to account for population variability in these parameters. For further details on 233 
UEf  see SI, Section S5. Eq. (3) was applied to each of the four paraben aggregate intake 234 
distributions to yield distributions for paraben urinary concentrations. The percentiles from these 235 
distributions can then be compared to the population based urinary concentration percentiles 236 
available from NHANES (50
th
, 75
th
, 90
th
, and 95
th
 percentiles for the years 2009-2010).
21
 237 
3. Results  238 
3.1 Paraben Product Intake Fraction 239 
The median product intake fraction during the use-stage, PiF
use
 ranged from 2-88% (2.5
th
-240 
97.5
th
 percentiles ranged from 0.1-99%) across the product-chemical combinations, with the 241 
highest PiF
use
 for EtP in body lotion and the lowest for EtP in conditioner (Figure 1). This 242 
indicates that a substantial fraction of the parabens in cosmetics penetrates the skin (Figure S2). 243 
In contrast, the mean environmentally mediated PiF
disp
 was three to four orders of magnitude 244 
lower than PiF
use
 for all product-chemical combinations, ranging from 10
-4
 – 10-3 % with the 245 
highest PiF
disp
 for PrP in shampoo and the lowest for EtP in body lotion. This implies that the 246 
focus can be on the use-stage exposure, which is substantially higher than environmentally 247 
mediated exposure, such that the disposal-stage was subsequently excluded from the Monte 248 
Carlo analysis. Within the use-stage, dermal aqueous uptake accounted for 78-99% of the total 249 
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PiF
use
 indicating that exposure to parabens in PCPs is dominated by direct dermal intake of 250 
chemical applied to the skin (Figure S2). As the second main impact pathway, gaseous dermal 251 
uptake accounted for 1 to 21% of PiF
use
 and inhalation represented only 0.1 to 1% of PiF
use
. 252 
Weschler and Nazaroff
44
 also found that dermal gaseous uptake exceeds the inhalation pathway 253 
for parabens.  254 
The large range in PiF
use
 for parabens is mostly due to the variation in the application 255 
duration of each PCP; PiF
use
 ranged from 6-50% for rinse-off products with a mean application 256 
duration of 4 minutes, and from 50-80% for leave-on products with a mean application duration 257 
of 14 hours. A plot of PiF
derm,aq 
versus time (Figure S3a) for the mean product thickness, h (0.01 258 
cm), shows that at 4 minutes (0.07 h), chemical uptake is still in the linear phase of the 259 
exponential (with PiF
derm,aq 
ranging from 0.2 – 0.4), whereas at 14 hours, uptake has reached its 260 
plateau. For parabens this plateau occurs for PiF
derm,aq 
at or above 80% at the mean product 261 
thickness indicating that parabens are readily absorbed into the skin, which has been observed 262 
empirically,
32,45
 whereas this plateau may occur at a substantially lower PiF
derm,aq
 for more 263 
volatile chemicals. This observation is in-line with Gouin et al.
46
 who suggested that wash-off 264 
products (as opposed to leave-on products) are likely the dominant source of PCP chemicals to 265 
WWTPs, noting that this depends on physicochemical properties. For a given chemical, 266 
increasing product thickness can also reduce the fractional aqueous uptake (although not 267 
necessarily the overall intake via this pathway); thus body wash (mean h = 0.003 cm) had a 268 
larger PiF
derm,aq
 than shampoo (mean h = 0.03 cm) (Figure 1) while both are rinse-off products 269 
(this is demonstrated in a plot of PiF
derm,aq
 versus time using the product thickness for body wash 270 
and shampoo (Figure S3b)). Overall, mean product thicknesses ranged from 10
-4
 (body lotion) to 271 
10
-2
 (shampoo) and are a function of the surface area of the application area and amount of 272 
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product applied (Table S1). The PiF
derm,aq
 was more sensitive to product thickness for rinse-off 273 
products as the uptake plateau is reached at 8 hours irrespective of leave-on product thickness 274 
(Figure S3b).  275 
3.2 Population level paraben intakes 276 
Figure 2 presents the relationship between the potential doses of chemical used (assuming 277 
100% product usage in the population and 100% paraben occurrence) and the effective chemical 278 
intake after the indicated adjustment (i.e. product usage, paraben occurrence, and PiF) to the 279 
previous adjustment. Adjusting for product usage reduced the potential dose by a factor of 1.4 280 
for the four parabens on average, and the subsequent adjustment for paraben occurrence reduced 281 
the potential dose by a factor 1.5 for MeP up to a factor 6 for BuP. Multiplying the effectively 282 
applied dose (i.e. after adjusting for product usage and occurrence) by the PiF reduced the 283 
population exposure by 3, 1.5, 4, and 2 times for MeP, EtP, PrP, and BuP, respectively. Overall, 284 
the final adjusted intakes were 7, 11, 13 and 20 times lower than the potential dose for MeP, EtP, 285 
PrP, and BuP, respectively. Cowan-Ellsberry and Robison
1
 also found that applying these 286 
refinements substantially reduced the population exposure of parabens in PCPs with reductions 287 
ranging from a factor 2 to 12.5. Using PrP as an example, body wash, shampoo, body lotion, and 288 
conditioner contributed most to the potential applied dose (26, 22, 18, and18%). Once the 289 
refinements were applied, body lotion and body wash dominated the total intake (38% and 28%, 290 
respectively), whereas shampoo and conditioner combined made up only 13% of the total intake 291 
due to lower exposure duration and PiF (Figure 2).  292 
Accounting for product co-use yielded the final modeled exposure distributions for the four 293 
parabens (Figure 3). Based on these distributions ~100, 75, 97, and 69% of the adult female 294 
population is exposed (i.e. with non-zero intakes) to MeP, EtP, PrP, and BuP, respectively which 295 
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compares well to 99, 42, 93, and 47% detection reported for all urine samples (i.e. representing 296 
the entire population) from NHANES
22
 (Figure S5, SI). The higher detection frequency we 297 
determined for female adults are consistent with the highest NHANES paraben urine 298 
concentrations for female adults compared to other population groups. MeP and PrP had the 299 
highest probability of exposure out of the four parabens (Figure 3), due to their higher frequency 300 
of occurrence, while the modeled EtP and BuP intakes were strongly reduced when considering 301 
occurrence (Figure 3).         302 
The mean (2.5
th
-97.5
th
 percentile) modeled population intakes were 0.2 (3×10
-3
-0.8), 0.03 (0-303 
0.2), 0.06 (0-0.3), 0.02 (0-0.1) mg kg
-1
 d
-1
 for MeP, EtP, PrP, and BuP, respectively (Table 2). 304 
These modeled mean intakes fall in-between those found by Cowan-Ellsberry and Robison
1
 and 305 
Guo and Kannan
12
 for paraben exposure due to PCPs (Table S9), noting that these studies did not 306 
take population variability into account.  307 
Since some consumers may indeed use all PCP types which may all contain a given paraben, 308 
we calculated a high-end intake without applying the exposure adjustments for population 309 
exposure (i.e. we did not adjust for product usage, paraben occurrence, and co-use), yielding 310 
doses of 8, 3, 4, and 2 mg kg
-1
 d
-1 
for MeP, EtP, PrP, and BuP respectively and are approximately 311 
an order of magnitude larger than the 99
th
 percentile stochastically based adjusted exposure 312 
estimates. While these high-end estimates of exposures may not necessarily be likely, they may 313 
be possible and provide upper end conservative exposure estimates. 314 
3.3 Conversion to biomonitoring levels and comparison to NHANES 315 
Combining urinary excretion rates with the modeled intakes (with all adjustments, i.e. product 316 
usage, paraben occurrence, and PiF
tot
) allows for conversion to urinary concentration 317 
distributions, which can be directly compared to the 50
th
, 75
th
, 90
th
, and 95
th
 percentiles of the 318 
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NHANES biomonitoring data. Modeled urine concentration percentiles reflect well the 319 
NHANES variation of three orders of magnitude across parabens and percentiles and were well 320 
correlated (R
2 
= 0.9 comparing the log). Modeled values were within a factor of three (except for 321 
one value) using the in vitro estimated values of .UEf  When taking uncertainty into account, all 322 
modeled values were in agreement with NHANES values (Figure 4). As discussed above, the 323 
effect of applying the PiF
tot
 reduced the product usage and paraben occurrence adjusted intakes 324 
on average by a factor of 1.5 to 4 (Figure 2) which is a reflection of the median PiF
tot
 being 325 
larger than 50% for the majority of the products (i.e the leave-on products). This indicates that 326 
the three orders of magnitude variation in the biomonitoring data is not only a function of the PiF 327 
but also population variability and the other included exposure adjustments. The comparison to 328 
biomonitoring data suggests that the estimated PiFs for parabens are within an order of 329 
magnitude of actual intake fractions. 330 
4. Discussion 331 
 The PiF is a useful metric to compare product specific chemical intake due to various 332 
near- and far-field exposure pathways and routes due to PCP use, and for differentiating 333 
exposure between leave-on and rinse-off products instead of assuming a fixed fraction of 334 
chemical absorbed into the skin, which may lead to overestimates of the exposure. For parabens, 335 
model results suggested that dermal aqueous and gaseous uptake were the dominant exposure 336 
pathways and the inhalation and far-field pathways were substantially lower in comparison. 337 
Gouin et al. (2013) suggested that the use-phase of PCPs may be used to estimate down-the-drain 338 
emissions of PCP chemicals and the framework presented here can also be applied in this 339 
context. Furthermore, the PiF for PCPs has an analytical solution and can be calculated based on 340 
physicochemical properties and product usage characteristics and thus lends itself to rapid 341 
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computational exposure estimates. While this study applied stochastic techniques in-line with 342 
Tier 2 exposure calculations
18
 to facilitate comparison with bioactivity data, the PiF modeling 343 
framework for PCPs can also be readily applied in Tier 1 screening assessments as recommended 344 
by Shin et al.
6
 345 
 Other exposure media for parabens include food and dust
19,38,39
, however these sources 346 
have been previously found substantially lower than PCPs.
1,12,39
 Soni et al.
19
 estimated that the 347 
highest likely food intake for MeP and PrP is 0.01 mg kg
-1
 d
-1
 (1 mg d
-1
 normalized to 75 kg used 348 
in this study), which is 20 and 6 times lower than our modeled mean intake due to PCP usage for 349 
MeP and PrP, respectively. The 95
th
 percentile food intake for the four parabens ranged from 10
-350 
4
-10
-6
 mg kg
-1
 d
-1
 based on measured food concentrations of parabens in U.S.
39
 Intake of the four 351 
parabens via dust based on measured dust concentrations was estimated to range between 10
-6
-352 
10
-9
 mg kg
-1
 d
-1
 
38
 and is several orders of magnitude lower than modeled PCP intakes.     353 
 To predict paraben intake accurately, it is crucial to account for product usage, paraben 354 
occurrence within products, and population variability. Accounting for these exposure 355 
adjustments and using modeled PiF for parabens in PCPs yielded agreement between modeled 356 
and NHANES urine concentrations. This indicates that a detailed exposure calculation taking 357 
into account the chemical and product dependent PiF, exposure probability, and population 358 
variability can be an effective method to predict population level chemical intake associated with 359 
PCPs. 360 
 Uncertainty on the fraction urinary excretion, ,UEf  is considerable when converting 361 
chemical intakes and the limited empirical data available in the literature for parabens resulted in 362 
high uncertainty in estimated urine concentrations. Physicochemical property based estimates of 363 
pharmacokinetic parameters have recently been made available
42,47
 and may be useful for 364 
 17 
 
comparing exposure with high-throughput toxicity data for a larger number of chemicals. While 365 
the mean modeled urine levels overestimate those of NHANES the R
2
 of 0.87 for the log fit of 366 
modeled versus measured indicates that the modeling approach presented here was able to 367 
capture the exposure patterns of the four parabens well.    368 
 An additional challenge when estimating aggregate exposure is to effectively take into 369 
account product co-use.
1
 While several PCP usage studies report some data on product co-use, 370 
this information cannot be practically applied to a comprehensive PCP study as the data 371 
presentation is often incomplete; for example, only the most commonly used combinations, the 372 
correlation between the use of two products (rather than multiple products), or data on different 373 
sets of PCPs are presented,
1,48,49
 and certain PCPs of interest are not included in that dataset. By 374 
accounting for the probability of using a product, we were able to provide an initial reasonable 375 
estimate of product co-use, which could be complemented by multiple product usage conditional 376 
probabilities. Furthermore, co-use becomes even more complex when chemicals occur in 377 
different product types, for example PCPs and cleaning products and alternative methods for 378 
taking co-use into account may be needed.  379 
 Within the context of risk screening, the exposure refinements needed for a population 380 
level calculation may not necessarily be needed to calculate exposure for high-end product users 381 
(for example, those who use several PCPs with high-end product masses within the intended 382 
product usage) to protect all users rather than an average user. For example, exposure estimates 383 
can be compared with the allowable daily intake (ADI) to inform risk of parabens in PCPs. 384 
While there is no ADI for EtP and BuP, the combined ADI for MeP and PrP in the European 385 
Union is 0-10 mg kg
-1
 d
-1 19,23
 which is within an order of magnitude of both the high-end user 386 
 18 
 
combined intake of 12 mg kg
-1
 d
-1
 and the 99
th
 percentile stochastically estimated intake (with 387 
exposure adjustments) of 1.5 mg kg
-1
 d
-1
.  388 
  We presented a detailed population level PCP exposure model which is able to predict the 389 
three orders of magnitude of variation in NHANES paraben urine concentrations. The PCP 390 
product intake fraction model can be readily incorporated into rapid exposure models and can be 391 
combined with concentration databases such as the recently released Consumer Product 392 
Chemical Profile database CPCPdb
26
 to estimate chemical intakes due to PCP use. 393 
 394 
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 546 
Tables 547 
 MeP EtP PrP BuP Notes and Reference 
logKaw
 
-5.6 -6.0 -5.2 -4.9 Calculated from solubility and 
vapor pressure, EPI Suite 
50
. 
Values listed here are at 25 ºC 
and were corrected to skin 
temperature of 32 ºC for use in 
the model (see Sec. S.1). 
aq
pK (cm h
-1
)  
(geometric mean, GSD
2
) 
0.012, 
31 
0.009, 
19 
0.009, 
31 
0.023, 
31 
Lognormal distribution. See 
Table S3
a
 
gas
pK (cm h
-1
) 
(geometric mean, GSD
2
) 
4200, 
28 
10000, 
28 
1400, 
28 
1800, 
28 
Lognormal distribution. 
Geometric mean calculated 
using equation in Table S1. 
GSD
2
 was set to the mean of 
aq
pK GSD
2
.Values are at 25ºC 
and were corrected to skin 
temperature. 
fp shampoo (%) 
(low – high) 
0.01 
to 
0.2 
0 
to 
2×10
-4
 
1×10
-
3
 to 
0.2 
2×10
-
4
 to 
0.045 
Uniform distribution. See 
Table S4
b
 
fp body lotion (%) 
(low – high) 
0.01  
to  
0.29 
0.01  
to  
0.2 
0.01 
to  
0.2 
0  
to 
0.085 
Uniform distribution. See 
Table S4
b
 
fp range for all products % 
(low – high) 
8×10
-6
 
to 
0.5 
0  
to  
0.35 
0 
to 
0.28 
0  
to 
0.27 
Uniform distribution. See 
Table S4
b
 
Mp shampoo (g d
-1
) 
(2.5
th
 -97.5
th
 percentile) 1.7 to 34  
Gamma distribution. 
35
 
Mp body lotion (g d
-1
) 
(2.5
th
 -97.5
th
 percentile) 2.5 to 21 
Gamma distribution. 
34
 
Mp range for all products  
(g d
-1
) 
 
8×10
-4
 to 44 
(Min 2.5
th
 – max 97.5th 
percentile) 
34–36
. See Figure S1 
Table 1: Summary input data for main model parameters for methyl, ethyl, propyl, and butyl 548 
paraben. Further information and input data can be found in the SI. Notes: 
a
See Table S3 for 549 
references. 
b
Based on data from 
1,12,37
. GSD
2
 = geometric standard deviation squared. 550 
551 
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 553 
Figures 554 
 555 
Figure 1: Modeled total product intake fraction (PiF
tot
) for the 11 personal care products for 556 
MeP, EtP, PrP, and BuP (from left to right). The circles represent the median, the solid boxes 557 
represent the 25
th
 and 75
th
 percentiles, and the lines represent the 2.5
th
 and 97.5
th
 percentiles of 558 
PiF
tot
 calculated using Monte Carlo simulation.   559 
560 
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 561 
 562 
 563 
Figure 2: Reduction in potential applied chemical dose due to population PCP usage, paraben 564 
occurrence in products, and product intake fraction to yield the mean dose taken in for each 565 
product-chemical combination calculated by Monte Carlo simulations. The reductions were 566 
applied sequentially, thus the last column represents the dose based on all three reductions.  567 
568 
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 570 
 571 
 572 
 573 
Figure 3: Modeled log intake (mg kg d
-1
) distributions for the four parabens taking into account 574 
probability of exposure and product co-use. The grey solid vertical lines indicate the population 575 
with zero exposure (zero intakes were adjusted to a nominally low value (1×10
-15
) to make them 576 
visible on a log scale). The dashed line indicates the geometric mean of the exposed population 577 
and the black solid line indicates the geometric mean of the entire population (with adjusted zero 578 
intakes). 579 
580 
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 583 
Figure 4: Modeled urine concentrations from the Monte Carlo calculations versus NHANES 584 
urine concentrations. Vertical error bars on the modeled values represent uncertainty in fraction 585 
urinary excretion and horizontal error bars on the NHANES values represent the 95
th
 confidence 586 
interval on each percentile. The solid line indicates perfect agreement between modeled and 587 
measured values (1:1 line).  588 
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